Pharma

  • add this feed to my.Alltop

    FiercePharma

  • Jimenez counts on 7 drugs to take Novartis past Diovan

    Tracy Staton
    27 Jan 2012 | 11:22 am
    Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post-Diovan future. After the Swiss drugmaker loses patent protection on the blood-pressure blockbuster later this year, other products will actually fill the gap, he told Barron's at the World Economic Forum. And he's not even talking up yet-to-be-approved drug candidates, but meds that are already on the market. Seven Novartis drugs have blockbuster potential, Jimenez says, including the diabetes drug Galvus, with $700 million in 2011, and the cancer…

  • Sanofi, Novartis favor diagnostics partnerships over M&A

    Tracy Staton
    27 Jan 2012 | 11:11 am
    The initial speculation--or was it a wish?--that a Sanofi ($SNY) or Novartis ($NVS) might mount a counterbid to Roche's hostile $5.7 billion offer for Illumina was chilled rather effectively by a story from Reuters, in which the CEO of the respective companies pour cold water all over the idea.It's not that either company isn't sold on personalized medicines and the diagnostic tools needed to identify patient populations. They're just not wild about the idea of paying billions for the companies to get access to gene sequencing technology when there are other ways to accomplish the…

  • Amgen's new meds beat estimates as anemia drugs slip

    Tracy Staton
    27 Jan 2012 | 10:56 am
    Amgen's ($AMGN) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen. New bone drugs Xgeva and Prolia beat analyst estimates for their first full year on the market with $554 million in sales. Report

  • Europe makes Sanofi chief thankful for emerging markets

    Tracy Staton
    27 Jan 2012 | 10:50 am
    Although Sanofi ($SNY) CEO Christopher Viehbacher (photo) sees a glimmer of light at the end of the long Eurozone tunnel, he's still glad the French drugmaker doesn't depend on Europe as much as it used to. "I'm very glad I invested heavily in emerging markets three years ago, because there's clearly a difference now in the growth in our industry," Viehbacher told CNBC at Davos, on the sidelines of the World Economic Forum. The U.S. and Europe used to be the center of the pharma universe, but like Sanofi, other Big Pharmas have been casting a wider net, investing in India, China, Latin…

  • Nexium, Actos, or Diovan? Analysts try to ID Ranbaxy's 3 sacrifices

    Tracy Staton
    27 Jan 2012 | 10:22 am
    Now that the dust has settled around Ranbaxy Laboratories' deal with the U.S. Justice Department, three missing bits of information are looming large. Which three first-to-file exclusivity rights will Ranbaxy lose? The identity of those drugs, filed under court seal, is obviously important in determining the consent decree's financial impact. Ranbaxy has 8 pending applications accorded that first-to-file status, which gives generic drugmakers 6 solo months on the market. On a major drug, that 6 months can mean major money, because the first copycat drug can command higher prices. Once other…
 
  • add this feed to my.Alltop

    Drugs.com - Daily MedNews

  • Too Much Fructose Sweetener Tied to Heart Risks in Teens

    27 Jan 2012 | 4:01 pm
    FRIDAY, Jan. 27 -- Teens who consume large amounts of the food and beverage sweetener fructose show evidence of cardiovascular disease and diabetes risk in their blood, a new study finds. Fructose is found in fruits, while a form of fructose --...

  • Discrimination Seems to Harm Health Regardless of Race

    27 Jan 2012 | 4:00 pm
    FRIDAY, Jan. 27 -- Discrimination can be a threat to health, according to a new study that included both blacks and whites. The analysis of 2004 data from the ongoing U.S. Behavioral Risk Factor Surveillance System project found that about 18...

  • Off-Campus Party Hosts Drank Most in College Survey

    27 Jan 2012 | 3:01 pm
    FRIDAY, Jan. 27 -- College students who host off-campus parties drink more than their guests, according to a study, which also found that hosts tend to be males, members of a fraternity, in their sophomore year or higher and have more money to spend...

  • Bydureon Approved for Type 2 Diabetes

    27 Jan 2012 | 3:01 pm
    FRIDAY, Jan. 27 -- Bydureon (exenatide extended release), Amylin Pharmaceuticals' long-acting version of the diabetes drug Byetta, has been approved by the U.S. Food and Drug Administration. The once-weekly injection will include a label warning...

  • Students Report Playing Dangerous 'Choking Game'

    27 Jan 2012 | 3:00 pm
    FRIDAY, Jan. 27 -- The "choking game" has been played by nearly one in seven students who were surveyed at a Texas university, a new study finds. This so-called 'game' is played individually or in groups and involves deliberately cutting off blood...
 
 
 
  • add this feed to my.Alltop

    MedWorm: Pharmaceuticals

  • US Drug Watchdog Expands Its Initiative To Identify Women Who Used The...

    26 Jan 2012 | 11:33 pm
    The US Drug Watchdog says, "Its hard to comprehend what it might be like for a middle aged, or older woman, who was taking the Osteoporosis drug called Fosamax, who had an unexplainable broken...(PRWeb January 25, 2012)Read the full story at http://www.prweb.com/releases/2012/1/prweb9123929.htm (Source: PRWeb: Medical Pharmaceuticals)MedWorm Sponsor Message: Find the best January Sales in the UK.

  • Manufacturing Highly Potent Compounds - Understanding and Controlling...

    26 Jan 2012 | 11:33 pm
    Affygility Solutions is pleased to announce the release of its newest webinar, "Manufacturing Highly Potent Compounds - Understanding and Controlling the Risks." In this two-hour long...(PRWeb January 25, 2012)Read the full story at http://www.prweb.com/releases/2012/1/prweb9134171.htm (Source: PRWeb: Medical Pharmaceuticals)

  • DrBicuspid.com Announces Winners of 2012 Dental Excellence Awards

    26 Jan 2012 | 11:33 pm
    The Dental Excellence Awards categories range from Most Influential Dental Researcher to Best Practice Management Consultant and Best New Diagnostic Device.(PRWeb January 24, 2012)Read the full story at http://www.prweb.com/releases/2012/1/prweb9134475.htm (Source: PRWeb: Medical Pharmaceuticals)

  • Roboz Surgical Displays New Dissecting Scissors in Georgia Exhibitions

    26 Jan 2012 | 11:33 pm
    Roboz Surgical announces that it will participate in two exhibitions in Georgia in February.(PRWeb January 26, 2012)Read the full story at http://www.prweb.com/releases/dissecting_scissors/Georgia_shows/prweb9133504.htm (Source: PRWeb: Medical Pharmaceuticals)

  • Sparta Systems to Sponsor Free Webinar on Managing Quality in the...

    26 Jan 2012 | 11:33 pm
    Sparta Systems, Inc., the market leader in enterprise quality and compliance management solutions, today announced that it will sponsor a webinar titled “Managing the Complex Supply Chain Ecosystem,”...(PRWeb January 24, 2012)Read the full story at http://www.prweb.com/releases/2012/1/prweb9133906.htm (Source: PRWeb: Medical Pharmaceuticals)
 
  • add this feed to my.Alltop

    Pharma Marketing Blog

  • Allergan "Badly Let Down" by Employee Tweet

    27 Jan 2012 | 9:34 am
    The Prescription Medicines Code of Practice Authority (PMCPA) ruled that Allergan breached UK pharma's self-regulatory Code of Practice because an employee accidentally tweeted publicly about Botox (read the details here "Brits Versus Botox Tweet"). Basically, an employee sent a public tweet to a friend in which he/she mentioned Botox and said "... we could do something around stroke rehab..."

  • Taking the "Cool" Way Out of Having Rx Product Convos on Social Media

    27 Jan 2012 | 7:35 am
    I have criticized pharma companies for mentioning Rx brand product names via social media. Mostly because they forget to include fair balance or don't educate the public (see, for example, "Novo Nordisk's Branded (Levemir) Tweet is Sleazy Twitter Spam!"). That doesn't mean, however, that I don't believe there is a way for pharma to engage in branded product discussions via social media such as

  • Should Pharma Disclose Payments to Celebrity Spokespeople?

    26 Jan 2012 | 12:39 pm
    In my podcast interview of Ambre Morley (listen here or read it here: "Novo Nordisk Defends Choice of Paula Deen as Diabetes Spokesperson"), Associate Director, Product Communications, Novo Nordisk, I brought up the subject of compensation for celebrity pharma spokespeople like Paula Deen, the celebrity chef who was recently hired by Novo Nordisk as a diabetes spokesperson. Obviously, Paula Deen

  • Did FDA Entrap Google with Those 14 NOV Letters?

    25 Jan 2012 | 6:00 am
    Con Artist Reveals All About Google Drug Ad Sting - How FDA May Have Entrapped Google Using Those 14 "Infamous" Notice of Violation Letters In an interesting article in today's Wall Street Journal, a convicted con artist details how he was employed by federal agents -- including agents of the FDA's Office of Criminal Investigation -- to lead a sting operation against Google's illegal drug ad

  • Is There a Cure for Mediocre Pharma Mobile Apps?

    20 Jan 2012 | 8:39 am
    For new pharma marketing Graduates, I have just one word for you. Are you listening? Mobile! Mobile is the new "shiny thing" of interest to pharmaceutical marketers. As evidence of this, there are more and more drug industry conferences that are dedicated to mobile or have tracks or whole days dedicated to mobile. Mobile Healthcare Communications 2012, for example, is one of them. I will be at
  • add this feed to my.Alltop

    BioSpace.com Featured News and Stories

  • Pfizer Inc. Sued by Employees Over Retirement Plans

    27 Jan 2012 | 6:00 am
    Employees of Pfizer Inc. have filed suit against the company, alleging the world's largest drug maker failed to properly manage its retirement plans and caused losses totaling hundreds of millions over the past decade in one of the hubs of the pharmaceutical industry. The suit, filed Wednesday in federal court in Puerto Rico, alleges Pfizer allowed employees to amass such high concentrations of company...

  • Rivals See No Need to Match Roche's Big Gene Bet

    27 Jan 2012 | 6:00 am
    Roche Holding AG's rivals Sanofi SA and Novartis AG see no need to match the Swiss drug maker in buying a gene-decoding business like Illumina Inc and reckon they can do partnerships instead. The relaxed attitude in the face of Roche's $5.7 billion hostile bid for Illumina suggests the chance of a counterbid from big drug makers is slim, although diagnostics and IT companies may yet show interest...

  • Verastem, Inc. Bucks the Trend, Raises $55 Million in IPO

    27 Jan 2012 | 6:00 am
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold...

  • Bristol-Myers Squibb Company Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of Strategic Transactions and Good Operating Performance

    27 Jan 2012 | 6:00 am
    NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY and NULOJIX in both the U.S. and Europe, and ELIQUIS in Europe for the prevention of venous thromboembolic events. Business development remained a top priority as...

  • Why Biogen Idec, Inc. (Massachusetts) Got Out of the Corporate VC Business

    27 Jan 2012 | 6:00 am
    Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French.
 
 
  • add this feed to my.Alltop

    Pharma Strategy Blog

  • A new opportunity for vemurafenib in BRAFV600E colon cancer

    MaverickNY
    26 Jan 2012 | 2:12 pm
    There’s been quite a flurry of commercial news on the Pharma front this morning, with Amgen buying Micromet (whose leading product is blinatumumab in ALL) and Celgene announcing their acquisition of Avila Therapeutics who have a Bruton Kinase Inhibitor (BTK) AVL-292 in phase IB development for lymphomas, which was all the rage at the recent American Society of Hematology (ASH) meeting last month. The big news for me today, though, wasn’t the commercial acquisitions but a gem of a paper relating to science and its significance for future cancer treatment. One of the unsolved…

  • Unravelling early colorectal cancer: the links between ROS, DNA methylation and inflammatory responses

    MaverickNY
    24 Jan 2012 | 11:56 am
    During yesterday’s discussion with Dr Ray DuBois (MD Anderson Cancer Center) about inflammation and methylation, the topic of CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) came up as you can see from the brief audio clip below: Steve Baylin’s paper sounded most interesting, so I tracked it down – see O’Hagan et al., (2011) in the References below for the direct link. CIMP is interesting to look at because it can occur in some 30% of colorectal cancer cases and has been previously shown to be an independent predictor of survival with 5FU in early or adjuvant CRC…

  • New research demonstrates the link between inflammation and early development of colon cancer

    MaverickNY
    23 Jan 2012 | 11:29 am
    Recently, epigenetics has been very much to the forefront with promising new human data in lung and breast cancers. Nature Medicine This morning I was therefore thrilled to see some exciting work just published in Nature Medicine Online First from Ray DuBois’s lab at MD Anderson Cancer Center, on the potential role of inflammation and silencing of tumour suppressor genes in early colorectal cancer. Previously, the group looked at the role of COX-2 in intestinal inflammation and colorectal cancer and observed that: “A large body of evidence indicates that genetic mutations, epigenetic…

  • miRNA as a potential biomarker for early breast cancer

    MaverickNY
    16 Jan 2012 | 10:18 am
    One way to potentially improve long term cancer statistics is earlier detection, and in high risk patients, appropriate initiation of earlier treatment, since it is well known that the survival in stage II or III breast cancer is noticeably better than that for stage IV metastatic disease. A critical question then, is how do we improve earlier detection? There are a number of ways to achieve this: Imaging techniques Prognostication Diagnostics Biomarkers Historically, breast cancer has often been picked up using classic, but rather crude, imaging techniques such as mammography and ultrasound,…

  • Gene mutation and resistance to chemotherapy in colorectal cancer

    MaverickNY
    5 Jan 2012 | 3:03 pm
    This week’s New England Journal of Medicine (NEJM) contained a fascinating article on how a specific gene mutation known as Transcription factor AP-2 epsilon, TFAP2E–DKK4, appears to be responsible for inducing at least some of the resistance to chemotherapy that occurs during treatment of colon cancer. At first sight, I wasn’t sure from the abstract if they were referring to either adaptive resistance to therapy or whether genetic changes already present limited the effectivenes of the treatment. Further reading of the full article more specifically pointed to the latter: “Epigenetic…
  • add this feed to my.Alltop

    PharmaGossip

  • A father’s anguish: Military killed my son with prescription pad | The Daily Caller

    insider
    28 Jan 2012 | 2:43 am
    Ads by GoogleLatest Energy ResearchRenewable energy and climate change report from the IPCC. www.cambridge.org/renewable A generic photo of prescription drugs taken March 20, 2009 for files. (PAUL J. RICHARDS/AFP/Getty Images) A father who has lost two sons to war told The Daily Caller that the U.S. Central Command’s policy of allowing troops to deploy with a 180-day supply of the antipsychotic Seroquel has contributed to the deaths of troops and veterans. Seroquel, he said, has tragic side effects that military leaders have ignored in their quest to combat insomnia and post-traumatic…

  • Senate Watchdog Targets High-Prescribing Medicaid Docs - ProPublica

    insider
    27 Jan 2012 | 8:43 pm
    via propublica.org Posted via email from Jack's posterous

  • Bydureon, a Diabetes Drug from Amylin, Wins F.D.A. Approval - NYTimes.com

    insider
    27 Jan 2012 | 7:58 pm
    Analysts expect annual sales of Bydureon to eventually exceed $1 billion. But they are less enthusiastic than they once were, in part because of safety concerns involving thyroid cancer and pancreatitis. David Kliff, publisher of Diabetic Investor, an electronic newsletter following the diabetes industry, said a once-weekly self-injection could make Bydureon an alternative for many patients to multiple insulin injections or even to multiple pills every day. via nytimes.com Posted via email from Jack's posterous

  • Harvard doctor calls for greater supplement regulation in NEJM | Drug Store News

    insider
    27 Jan 2012 | 1:07 pm
    WASHINGTON — The New England Journal of Medicine on Thursday published an opinion online that called for more rulemaking to govern dietary supplements in an effort to reign in the criminal activity of illicit prescription drug manufacturers that openly disregard the laws currently in effect. Author Pieter Cohen, author of the opinion and an assistant professor of medicine at Harvard Medical School, in his opening paragraph pointed to the recent recall of the product Zotrex. Marketed as a dietary supplement, the product reportedly contained the fictitious ingredient "Ophioglossum…

  • James Murdoch’s departure rings in changes to GSK’s board | InPharm

    insider
    27 Jan 2012 | 7:03 am
    GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will stand down from the board. In addition, the UK firm said that James Murdoch has decided not to stand for re-election. Sir Christopher Gent, chairman of GSK, said: “James Murdoch has decided to stand down from the board with effect from this year’s AGM.   via inpharm.com Posted via email from Jack's posterous
 
  • add this feed to my.Alltop

    Dose of Digital

  • Translating the New FDA Social Media Guidance

    Jonathan Richman
    4 Jan 2012 | 11:34 am
    [Get your copy of the FDA Guidance Translator Flow Chart later in this post] It’s been a long wait, but the FDA finally delivered. They’ve come through with at least some direction for how pharma companies can properly use social media. It’s not a complete answer to every issue, but it is a good start. I’ve reviewed the full contents of the guidance that the FDA released on December 30, 2011 and found it, not surprisingly, a bit hard to follow at times. The full title of the guidance they released is: “Responding to Unsolicited Requests for Off-Label Information…

  • Digital Marketing Lessons from 2011′s Top Memes

    Jonathan Richman
    14 Dec 2011 | 9:21 am
    I love memes. They’re simple. They get one point across. They tend to be amusing. I also like being “in the know” and there’s typically some backstory to the meme that you need to understand for it to make sense. It’s kind of like an exclusive club for the Internet set of us out there. What I really like about memes is how you can use them to express a really simple concept. For those of you who don’t really know what a meme is, here’s the official definition (thanks to Google’s handy “define” feature): An element of a culture or…

  • Pharma Companies That Have Proved Me Wrong

    Jonathan Richman
    9 Nov 2011 | 9:16 am
    It takes a big person to admit they’re wrong. This is especially true when it’s me, as I really don’t like doing this. Ever. Well, here comes one of those rare times where I do admit it. There is one caveat: I’m not totally wrong. Just partially wrong. You see, almost two and a half years ago I wrote a post called  Ten Digital Marketing Ideas Pharma Companies Will Never Try (But Should). It ‘s actually  the second most read post ever on Dose of Digital (second only to Facebook Pages Just Got Easier for Brands). That means about 8,000 of you will understand why…

  • The Right Way to Use the Facebook Like Button

    Jonathan Richman
    31 Oct 2011 | 8:35 am
    This has annoyed me for a long time, so I’m finally going to fix this for the entire world once and for all. You’ve probably all found yourself on a Facebook page and have seen something like this: (Try it out on the Oreo page for yourself). What’s annoying about this? Rather than including a Like button in the tab, they point you to the button at the top of the Page. Sometimes this is more egregious like in the case of BMW’s Page. From a design standpoint, I don’t know what’s visually less appealing than a giant arrow jutting out of your Page.

  • Visualizing Pharma’s Use of Social Media

    Jonathan Richman
    24 Oct 2011 | 2:57 pm
    A while back, I got a note from Leigh Householder (@leighhouse) who had the idea to take the Pharma and Healthcare Social Media Wiki and make it much more visual so people could appreciate just how much the pharma industry has dove into social media. Since infographics are all the rage these days, I gave her the go ahead. A few iterations later and her team at the IQ Lab at GSW developed this simple, yet elegant (I think) way to visualize pharma’s participation in social media. Rather than a bunch of confusing stats, Leigh’s team took a page (literally) from each of the existing…
  • add this feed to my.Alltop

    BioPharma Today

  • Coming In Monday's "The Pink Sheet" DAILY - Pfizer's Kidney Cancer Drug Inlyta Clears FDA

    Wendy Diller
    27 Jan 2012 | 12:18 pm
    Verastem completes its initial public offering - Neurocrine Biosciences and Prosensa are among financings of the fortnight - FDA approves Pfizer's kidney cancer drug Inlyta - FDA is to review Pfizer's myeloid leukemia drug bosutinib

  • Latest News From "The Pink Sheet" DAILY - Watson Launches Generic Lovenox At Risk

    Wendy Diller
    27 Jan 2012 | 9:27 am
    Watson's generic Lovenox launches at risk - LIO plays up rapid action of plant-based gel Picato for actinic keratosis - HHS proposed drug coverage standard for state exchange plans is below currently available coverage - Ariad has plans to become a global leader in oncology - Bristol-Myers Squibb predicts overall net sales decline for 2012 - Amgen acquires Micromet for $1.16 billion - Celgene bolsters its pipeline with Avila acquisition

  • Editors' Picks From The World Press

    Wendy Diller
    27 Jan 2012 | 9:12 am
    Business & Finance Drugmakers made fewer licensing deals in 2011 PharmaTimes (U.K.) Jan. 26, 2012 Illumina resists Roche bid with shareholder-rights plan Reuters Jan. 26, 2012 Amgen will buy Micromet for $1.16 billion Genetic Engineering & Biotechnology News Jan. 26,...

  • Coming in Friday's "The Pink Sheet" DAILY

    Wendy Diller
    26 Jan 2012 | 12:24 pm
    Celgene acquires covalent oncologic company Avila for $350 million upfront, as well as the potential for $575 million in milestones based on development of AVL-292 and the progress of the Avilomics platform.

  • Latest News From "The Pink Sheet" DAILY - No CKD Indication For Merck's Vytorin

    Wendy Diller
    26 Jan 2012 | 9:30 am
    For Novartis, 2012 Is Set To Be A Bumpy Ride
  • add this feed to my.Alltop

    Free Biotechnology & Pharmaceuticals Magazines and Downloads from alltop.tradepub.com

  • LCGC Europe

    4 Jan 2012 | 6:20 pm
    LCGC Europe aims to be the leading supplier of troubleshooting information and application solutions on all aspects of sample preparation, chromatography, capillary electrophoresis, hyphenated systems, and associated data handling and quality issues.Request Free!

  • Bioscience Technology

    3 Jan 2012 | 12:20 pm
    Each issue of Bioscience Technology covers new technologies and applications in life science research. It's sent to scientists doing biology-based research in pharmaceutical, academic, biotech, government and commercial labs. Bioscience Technology is printed 12 times a year and is available in Print or Digital format.Request Free!

  • Lab Manager Magazine

    3 Jan 2012 | 12:20 pm
    Most lab managers, by education and experience, are thoroughly capable of handling the technical aspects of their jobs, but their managerial skills are often obtained haphazardly. Lab Manager Magazine® is written with those managers in mind and has the distinct editorial mission of providing practical information on business, strategy, leadership and staffing as well as the industry and technology news needed to effectively manage today's lab.Request Free!

  • Surgical Products

    3 Jan 2012 | 12:20 pm
    Each issue provides information about new products, technology solutions, and industry insights in the surgical/healthcare field. Surgical Products is published 9 times a year (monthly except bi-monthly in Jan/Feb, July/Aug and Nov/Dec) and is available in Print or Digital format.Request Free!

  • Medical Meetings

    3 Jan 2012 | 11:20 am
    As a Member of the Medical Meetings Community you'll get:The latest on CME and pharma industry regulationsThought-provoking perspectives from respected industry expertsTips on managing conventions and attrition; marketing an educational activity, achieving cost-savings, using the latest technology, holding international meetings, and moreRequest Free!
 
 
 
  • add this feed to my.Alltop

    Medical Brochures Blog

  • Polycillin

    27 Jan 2012 | 5:54 am
    Product Definition : Polycillin belongs to a class of antibiotics called penicillins that are used for treating bacterial infections. Other members of this class include amoxicillin (Amoxil),... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • SevenSeas' BION3 brochures

    30 Dec 2011 | 2:50 pm
    v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} Normal 0 false false false ... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Anti-Cancer

    23 Dec 2011 | 9:58 am
    Excessive Exposure to Sun may cause skin cancer, Protect yourself. National Cancer fighting day, 27 Nov. http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Cont. Calorilight. Makes meals 50% lighter. Say goodbye to calories

    23 Dec 2011 | 9:53 am
    “Calorilight. Makes meals 50% lighter. Say goodbye to calories.” Advertising Agency: Euro RSCG 360, Paris, France Creative Director: Hugues Pinguet Art Director: Gael Caron Copywriter: Benoit... http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.

  • Nobilin

    23 Dec 2011 | 9:51 am
    Product Definition : Nobilin is categorized as digestive medicine Copy writing : teargets heavy food Artwork: strips pack design Please contribute with your critique! http://medical-brochures.blogspot.com/ the Pharmaceutical Archive of Medical Brochure s, Artwork Designs and Advertisements; to serve Pharmaceutical Marketers, Product Managers, Sales Managers, Medical Representatives, Doctors of different specialties and other Medical Professions.
  • add this feed to my.Alltop

    Impactiviti blog

  • Replacing Live Meetings

    Steve Woodruff
    13 Jan 2012 | 7:06 am
    As I spend time with a wide range of folks in the pharma space (sales, training, marketing), certain themes emerge across the board. One of those that comes up regularly these days is the effort to find replacements for live meetings. This includes regular meetings during the year (POAs); exceptional meetings (launch); and face-to-face training events (including initial sales training). We’re a long way into the era of none-too-glamorous e-learning apps, and basic webcasts are a commodity and a yawner. But now we’re moving into a time when internet access is increasingly…

  • Fresh Pharmaceutical Training Jobs

    Steve Woodruff
    16 Dec 2011 | 8:14 am
    Welcome back! First, a couple of links of interest to kick off the new year: :: Are Walnuts now Drugs? Ask the FDA! (Nanny state alert) :: Made-up Disease (YouTube) UPDATE: Some more jobs that have been posted in the past week or so, in addition to the original list! Director, Global Training and Development, Customer Management, J&J (NJ) Sales Trainer, Stryker, NJ Manager, Sales Training and Development, Eisai (NJ) Manager, Sales Training, Aptalis (NJ) Director/Sr Director, Commercial Training and Development, Regeneron (NY) Dir, Global Sales Training and Development, Alexion (CT) Sales…

  • Who Needs a Digital Strategy?

    Steve Woodruff
    2 Dec 2011 | 8:14 am
    Short answer: we all do. I’ve been spending a lot of my time lately with clients and partners working on digital strategies, including multi-year blueprints, next-generation platforms, and development approaches. It can be quite complex – and I live/love this stuff! For someone with a day job in pharma training, sales, and marketing, it’s difficult to take a long-term strategic view of our rapidly-moving technology environment and formulate a clear digital strategy. Yet we must. Pulling back the veil a bit from the image of these huge, money-generating global pharmaceutical…

  • Doc-Driven? Or Rep-Driven?

    Steve Woodruff
    11 Nov 2011 | 7:26 am
    We all know that the pharmaceutical sales model is being seriously re-thought. Every business model needs periodic review, to see if it continues to be a value-add, or if, in fact, it is losing effectiveness. The interrupt-driven model of having drug reps come to doctors’ offices for fewer and fewer minutes of discussion, plus dropping off of samples, is rapidly losing market favor. It’s costly and increasingly inefficient for the drug companies, and it fills offices with non-paying people jockeying for time and attention in a marketplace where both are scarce. So is there a…

  • Pharma Training Jobs (Oct 2011)

    Steve Woodruff
    28 Oct 2011 | 7:41 am
    Here’s a listing of various pharma training jobs I have found listed on-line in recent weeks. I do not have any affiliation with the listing companies; just providing these links as a service to you! Sr. Director, Commercial Training and Development, Regeneron (Tarrytown NY) Director Sales Training, Ferring (NJ) Manager, Sales Training and Development, Watson (NJ) Executive Director, USP and Leadership, BMS (NJ) Director, Global Training, Novo Nordisk (NJ) Sr. Manager, Commercial Training and Development, Medimmune (MD) Director, Global Training and Education, J&J (CA) Director,…
  • add this feed to my.Alltop

    Hooked: Ethics, Medicine, and Pharma

  • Another Planet Heard From: Sunshine Law is Useless

    24 Jan 2012 | 10:19 am
    I had not heard recently from Dr. Thomas Stossel of ACRE fame (see for example http://brodyhooked.blogspot.com/2010/04/federal-settlements-acre-perspective.html). However, the redoubtable Dr. Stossel now appears on the op-ed page of the Wall Street Journal ("Who Paid for Your Doctor's Bagel?" January 23, p. A17; subscription required), to inform us that the Sunshine Act provisions included in the Affordable Care Act, due to take effect later this year, are "toxic" and "inverts reality."I have felt for some time that Dr. Stossel lives on another planet. On his planet everything is just fine…

  • The Over-the-Top Prices for Cancer Drugs

    24 Jan 2012 | 9:56 am
    Our pal Merrill Goozner of GoozNews blog just posted this article in the Fiscal Times:http://www.thefiscaltimes.com/Articles/2012/01/23/New-Cancer-Drugs-Affordable-by-the-1-Percent.aspx#page1Gooz goes into the current problems caused by the high cost of new cancer drugs, relating facts such as:84% of oncologists report that treatment recommmendations are modified due to the patient's out-of-pocket costsDespite decreasing incidence of cancer, the National Cancer Institute projects a 27% rise in the cost of treating the 29 most common cancers by 2020Typical price tags:Johnson & Johnson's…

  • NPR: Forget the Serotonin Theory of Depression

    23 Jan 2012 | 11:18 am
    Alix Spiegel of NPR did a very nice story this morning on the serotonin theory of depression:http://www.npr.org/blogs/health/2012/01/23/145525853/when-it-comes-to-depression-serotonin-isnt-the-whole-storyShe quoted a number of notable psychiatric experts, but sadly not our friends Jeffrey Lacasse and Jon Leo, whom we have cited here previously:http://brodyhooked.blogspot.com/2011/01/what-do-we-really-know-about-depression.htmlAnyway the news report covered most of the bases--that scientists believe that attributing depression to a deficiency of serotonin is at best overly simplistic and at…

  • From Kalman Applbaum: How Pharma Does Business

    17 Jan 2012 | 11:13 am
    Thanks to my esteemed colleague Daniel Goldberg for alerting to to this post--http://somatosphere.net/2012/01/the-banality-of-corporate-corruption-janssen%e2%80%99s-reimbursement-department-takes-the-stand-risperdal-on-trial-cont%e2%80%99d.html--by our old friend anthropologist Kalman Applbaum, for example as summarized here:http://brodyhooked.blogspot.com/2010/06/how-does-drug-industry-exert-power.htmlDr. Applbaum, showing us once again that academic research is far from glamorous, is apparently camped out in a courtroom watching the unfolding of the whistle-blower case regarding the…

  • Peddling Useless Drugs: Paying Journals to Publish

    6 Jan 2012 | 7:32 pm
    I reprint the following from my post of November 21, 2011:I've previously mentioned the Primary Care Medical Abstracts program run by my friends Rick Bukata and Jerry Hoffman, in which subscribers receive a CD each month with commentary on 30 recently published papers from medical journals. Since both Rick and Jerry are concerned about the impact of Pharma marketing on medical science and practice, it's not uncommon for several of the papers each month to address topics of interest to this blog. The October, 2011 issue had an especially impressive bumper crop. Here are capsule summaries of…
 
  • add this feed to my.Alltop

    FDA Law Blog

  • Supreme Court Rules Federal Meat Inspection Act Preempts California's Ban on Slaughter of Non-Ambulatory Animals

    FDABlog HPM
    26 Jan 2012 | 6:21 pm
    By Riëtte van Laack – On Monday, January 23, 2012, the U.S. Supreme Court ruled that a California state law prohibiting the slaughter, processing, and sale of any non-ambulatory animals is preempted by the Federal Meat Inspection Act (“FMIA”). As we previously reported, under California's Downed Animal Law, section 599f of the California state penal code, prohibits the slaughter of any non-ambulatory livestock.  This law was adopted in 2008 as a reaction to the publication of an undercover video in 2008, showing workers at the California Westland/Hallmark Meat Co. cattle…

  • GAO Recommends Coordination and Assessment of Federal Efforts to Educate About Prescription Pain Reliever Abuse and Misuse

    FDABlog HPM
    25 Jan 2012 | 7:41 pm
    By John A. Gilbert, Jr. & Larry K. Houck – The Government Accountability Office (“GAO”) has issued a report focusing on federal agency efforts to educate prescribers and the public about prescription pain reliever abuse and misuse.  The report’s title, “Prescription Pain Reliever Abuse: Agencies have Begun Coordinating Education Efforts, but Need to Assess Effectiveness” telegraphs the report’s conclusion.  The report evaluates the nine programs to educate current and future prescribers and nine programs to educate target groups within the general public about prescription…

  • A New Hatch-Waxman DJ Jurisdiction Decision . . . . And an Added Twist

    FDABlog HPM
    24 Jan 2012 | 8:34 pm
    By Kurt R. Karst –       In a recent Hatch-Waxman decision from the U.S. District Court for the Northern District of Illinois (Eastern Division), the court denied Plaintiffs’ Seattle Children’s Hospital, Novartis Vaccines and Diagnostics, Inc., and Novartis Pharmaceuticals Corporation (collectively “Novartis”) Motion to Dismiss the lawsuit that they brought against Akorn, Inc. (“Akorn”) for lack of subject matter jurisdiction and granted Akorn’s Motion to Amend its Answer to include a claim for a declaratory judgment of noninfringement of U.S. Patent No. 5,508,269…

  • Leap Year and Hatch-Waxman – An Unusual Conundrum Years in the Making

    FDABlog HPM
    23 Jan 2012 | 6:37 pm
    By Kurt R. Karst –       It’s absolutely amazing how, after nearly 28 years, the 1984 Hatch-Waxman Amendments continue to provide surprises.  Consider the latest example we came upon recently (with a little help) involving PRISTIQ (desvenlafaxine) Extended-Release Tablets. FDA approved PRISTIQ under NDA No. 021992 in a leap year, on February 29, 2008 at 3:15 PM Eastern Time (within business hours).  PRISTIQ is listed in the Orange Book with a single patent – U.S. Patent No. 6,673,838 (“the ‘838 patent”) expiring on February 11, 2022.  PRISTIQ is also identified in the…

  • Congressional Representatives Press FDA For Action on Third-Party Audits

    FDABlog HPM
    22 Jan 2012 | 11:26 pm
    By Ricardo Carvajal – In tandem with the release of a House Energy and Commerce Committee staff report on last year’s outbreak of Listeria monocytogenes in cantaloupe, members of that committee sent Commissioner Hamburg a letter calling for reforms in the conduct and oversight of third-party audits.  Based on the findings of the Committee report, the letter calls for FDA to develop regulations and guidance to address the following issues noted with the third party audit of Jensen Farms (the producer of the cantaloupe implicated in the outbreak): The audit was geared only toward…
  • add this feed to my.Alltop

    Life Science Digest

  • 2011 Review and Outlook for Biotechnology in 2012

    MD Becker Partners
    25 Jan 2012 | 6:47 am
    In 2008, the Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. On the heels of such a miserable year, it may have seemed counterintuitive to provide a positive outlook for the speculative biotechnology industry in 2009, but that’s exactly what we did.  Our bullish thesis was reiterated for both 2010 and 2011. The AMEX Biotechnology Index (BTK) ended 2008 at 647.17 and climbed to 1,091.42 by the end of 2011 for a gain of approximately 69% during this three-year period.  Comparing this…

  • 2012 Preview: Cancer Immunotherapy Catalysts

    MD Becker Partners
    14 Dec 2011 | 5:00 pm
    Biotechnology stocks are known for volatility, as many industry executives, investors, and research analysts will attest.  Companies can achieve significant valuations long before their products generate revenue or trade below cash value following negative trial results.  In addition, biotechnology products may be subject to severe competition and rapid obsolescence, which only adds to the unpredictability. One recent example of this inherent volatility and achieving a lofty valuation prior to commercialization is Dendreon Corporation (DNDN).  On April 29, 2010, the FDA approved the…

  • Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

    MD Becker Partners
    23 Oct 2011 | 4:00 pm
    November marks Pancreatic Cancer Awareness Month.  According to the American Cancer Society, more than 44,000 new cases of pancreatic cancer will be diagnosed in the U.S. and over 37,000 deaths are expected from the disease in 2011.  It has the highest mortality rate of all major cancers; 74% of patients die within the first year of diagnosis and 94% of patients die within five years[1].  Out of the top 15 cancer sites, pancreatic cancer is the only one with a five-year relative survival rate in the single digits [6%][2]. Visibility for the disease is on the rise following the recent…

  • 2011 Cancer Immunotherapy: A Long-Awaited Reality

    MD Becker Partners
    11 Oct 2011 | 1:56 pm
    To view a slideshow selected photos from the 2nd Annual “Cancer Immunotherapy: A Long-Awaited Reality” conference hosted by MD Becker Partners and held at the New York Academy of Medicine on October 6, 2011, please click here.

  • Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

    MD Becker Partners
    18 Sep 2011 | 3:55 pm
    The FDA approval of sipuleucel-T [Provenge®], a patient-specific immunotherapy for androgen independent prostate cancer developed by Dendreon Corporation (DNDN), and ipilimumab [Yervoy®], the first immune check point molecule for melanoma by Bristol-Myers Squibb (BMY), has renewed interest in the concept of immunotherapy as an approach to cancer treatment. Often overlooked, however, adjuvants can be an essential part of an effective vaccine and could help advance the field even further. Adjuvants are substances that can: Accelerate the generation of robust, longer lasting immune responses…
 
  • add this feed to my.Alltop

    Drug Channels

  • Big Trouble in the VA Contract: Who will win?

    26 Jan 2012 | 7:00 am
    Yesterday, Larry Marsh at Barclays Capital reported that the much-delayed Department of Veterans Affairs pharmaceutical prime vendor (PPV) contract has been pushed back again, at least until late March. The delay appears to be caused by alleged “improper buying” from McKesson (NYSE:MCK), the current sole PPV. See Veterans agency knew of improper buying under McKesson contract. The House Committee on Veterans' Affairs will hold a hearing on the PPV next Wednesday called Examining VA's Pharmaceutical Prime Vendor Contract. Below, I take a totally unscientific guess at which…

  • Drug Channels News Roundup: January 2012

    24 Jan 2012 | 7:00 am
    This month’s selection of noteworthy news stories looks at broader health care cost containment debate. Depressing news on disease management A fascinating debate on ACOs The sad realities of U.S healthcare spending Plus, watch The Daily Show’s Jon Stewart lob softball questions at Secretary of Health and Human Services Kathleen Sebelius, who does some major pre-State of the Union spinning. P.S. Reminder: The launch discount for the 2011-12 Economic Report on Retail and Specialty Pharmacies ends today! Read more »Copyright © 2006-2012 Pembroke Consulting, Inc. and Copyright © 2006-2012…

  • A Defense of Co-Pay Cards

    19 Jan 2012 | 6:00 am
    Pharmaceutical Executive just published a fascinating article by my friend Mason Tenaglia called Letting the Facts Get In the Way. Based on his firm’s analysis of various data sources, Mason provides a spirited defense of co-pay offset programs. He argues that co-pay cards don't increase utilization of higher-cost brand-name drugs and don't reduce generic usage, but do increase adherence. While the article lacks sufficient details to fully evaluate its empirical claims, it still makes a useful contribution by explaining how and why co-pay offset programs can be a valuable benefit…

  • Is Pfizer's Lipitor Strategy Working?

    18 Jan 2012 | 6:00 am
    Since November 30, the atorvastatin market has been split between Pfizer’s heavily-discounted brand-name Lipitor product, an authorized generic from Watson, and the first-to-file generic Ranbaxy. See Ranbaxy Makes Three: The Battle for Generic Lipitor Profits. Pfizer has been criticized for its unorthodox discounting strategy. Surprisingly, Lipitor share is tracking below historical generic substitution patterns from the past few years, i.e., the brand-name version is losing share faster than a typical generic drug. The chart below tells the story, which is about as unexpected as an…

  • New Data on Specialty Pharmacy’s Challenge to Buy-and-Bill

    17 Jan 2012 | 7:00 am
    You should check out the new 2011 ICORE Medical Pharmacy and Oncology Trend Report (free download with registration). This 60-page report provides a wealth of interesting data on the specialty drug benefit management. The ICORE payer data confirms that the specialty pharmacy channel is displacing buy-and-bill in the physician office market. As I discuss below, this shift is occurring via white bagging of specialty drugs. Buy-and-bill will not end for all physician-infused drugs, but there are substantial pressures for certain therapies. White bagging has important implications for specialty…
  • add this feed to my.Alltop

    fiercedrugdelivery.com

  • Nanotech transforms cyclosporine into safer transplant drug

    Mark Hollmer
    27 Jan 2012 | 1:23 pm
    Scientists are eyeing nanotech drug delivery as a way to help reduce organ transplant failures. The Times of India reports that researchers at the University of Strathclyde in Scotland are working on a nano-sized drug particle version of cyclosporine, which is used already to help prevent organ rejection. Doctors would encapsulate the drug inside the nanoparticles to make sure it stays at its maximum concentration, and then trigger the compound to release slowly in order to avoid side effects the conventional dose can trigger, such as kidney and liver damage. The drug is typically given…

  • Report: Roche transferring Israeli diabetes operations to Europe

    Mark Hollmer
    24 Jan 2012 | 3:47 pm
    Less than two years after paying $200 million for diabetes pump developer Medingo, Roche's diagnostic division ($RHHBY) is shutting down the company and transferring its operations from Israel to Europe. The Israeli newspaper Globes reported the news Jan. 22. Roche's acquisition of the Israeli company gave it some nifty technology--a semi-disposable insulin-dispensing patch and a remote control to adjust insulin delivery. FierceMedicalDevices reported back in 2010 that Roche had hoped to launch the tech globally by 2012, assuming it received necessary approvals. Globes said that Medingo's…

  • This could be the year of nanotech-enabled medicines

    Mark Hollmer
    24 Jan 2012 | 3:09 pm
    Nanotech-enabled medicines are coming of age. That's the big message I came away with after a recent telephone chat with Kevin Bitterman, a life sciences investor with Polaris Venture Partners in Waltham, MA. He couched that statement with some history. Nanotechnology as it relates to life sciences generated buzz as early as 2000, Bitterman explained. But Polaris didn't make its first initial investments in the space until 2006-2008. And he sees some of those investments bearing fruit today, in a way that they may not have when the technology first gained attention. Bind Biosciences is…

  • University of Arkansas heightens nanomedicine research efforts

    Mark Hollmer
    24 Jan 2012 | 10:44 am
    Another player is joining the field of nanomedicine-related research and development: The Arkansas Nanomedicine Center. To be housed at The University of Arkansas' College of Medicine, the new institution will gather the university's 35-plus faculty members from various departments who are pursuing or thinking of pursuing nanomedicine-related research under one umbrella, according to Arkansas News. The goal is to encourage researchers from different disciplines with the same interests to work together toward figuring out innovative nanomedicine-related treatments that could cure disease or…

  • Alexza's Adasuve slapped with delayed FDA review

    Mark Hollmer
    24 Jan 2012 | 10:00 am
    The FDA slammed Alexza Pharmaceuticals ($ALXA) with another setback this week in its drive to bring the antipsychotic drug Adasuve to market. Regulators are extending by three months their review of the drug--an inhaled, fast-acting formulation--which will hopefully be completed now by May 4. FDA's original review deadline was Feb. 4. Adasuve is a vaporized form of loxapine, a longtime antipsychotic that has been available orally to treat adults for schizophrenia-related agitation or bipolar I disorder. Alexza houses the drug in its proprietary hand-held Staccato inhalation device that…
 
  • add this feed to my.Alltop

    trinitypharmasolutions.com

  • Five Trends in Commercial Pharma for 2012

    Zackary King
    25 Jan 2012 | 2:37 pm
    As we usher in another year, there are clear signs indicating where the pharmaceutical industry will be focused in 2012. While each company will have its own specific goals, there are emerging indicators that they will focus on embracing innovative technology as an overarching theme.read more

  • SaaS Business Intelligence - it just makes sense

    Zackary King
    19 Dec 2011 | 5:07 am
    I spoke recently to the commercial leaders of a well-established pharma company who were relaying their frustrations with their current data and business intelligence environment.read more

  • Introducing Agile M - Mobile Sales Insights for Life Sciences

    Zackary King
    5 Dec 2011 | 5:31 am
    Since its introduction last year, the iPad has quickly become the life sciences industry’s preferred mobile tool for sales and marketing.read more

  • Getting the Most from a National Campaign at the Local Level

    Brian Irwin
    15 Nov 2011 | 3:35 pm
    Managing the pull-through of a successful national brand campaign at the local level is always challenging for a sales force.read more

  • Pharma CRM: The Good and the Bad

    Zackary King
    10 Oct 2011 | 3:51 pm
    When deploying or upgrading Customer Relationship Management (CRM) systems, pharmaceutical companies have experienced varying degrees of success. At its most basic level, the primary function of a CRM system is to make your sales force successful in developing and maintaining strong relationships with customers.read more
  • add this feed to my.Alltop

    Pharmaceutical Sales Drug Representative Jobs Blog

  • January Is Pharmaceutical Sales Meetings Month

    Clint Cora
    12 Jan 2012 | 2:39 pm
    photo credit: somaya Pharmaceutical Sales Meetings Just in case if you are trying to do any networking with drug reps out there, January is typically sales meetings month when companies have their big first sales force meeting to kickstart the year.  This might even run into February too so don’t be surprised if it’s a bit tricky to catch any of the drug reps in your area right now. But they will be back on territory soon so don’t give up your networking efforts. Take the time to put the concepts learned in ‘How To Get A Dream Job In Pharmaceutical Sales –…

  • Pharmaceutical Sales Jobs Rehires After Layoffs

    Clint Cora
    12 Dec 2011 | 11:27 am
    photo credit: CarbonNYC Pharmaceutical Sales Jobs I will be doing a consulting project for one of the big pharma companies this month and it’s actually a repeat client since I did a similar one for them last year working for their drug representatives for a few days.  In addition to being a business speaker, I also do these consulting projects on the side. I know that they went through a layoff earlier this year but as I scan the names of the drug representatives I’ll be working with this month, I notice a lot of new names. Although there were many of the same names from last…

  • Interpersonal Skills For Pharmaceutical Sales Rep Or Medical Rep

    Clint Cora
    3 Nov 2011 | 7:55 am
    photo credit: caffeina Interpersonal Skills Pharmaceutical Sales Rep Since I’m in the midst of doing some diversity training presentations at colleges and non-profit organizations, I might as well outline one of the tips I present.  This is a very useful interpersonal skills tip to develop for the pharmaceutical sales rep or medical rep especially since how diverse the medical field is these days. Given the diverse working environment in medicine and healthcare, we should be able to use good interpersonal skills with all sorts of people including those from other cultures and…

  • Motivational Sales Quotes For Pharmaceutical Reps

    Clint Cora
    2 Nov 2011 | 2:44 pm
    Motivational Sales Quotes Here is a nice list of motivational sales quotes posted to my Motivation Facebook page over the last two weeks.  They are very applicable to pharmaceutical reps. “It is only the first step that is difficult.” ~ Marie De Vichy-Chamrond “When angry, count ten before you speak; if very angry, a hundred.” ~ Thomas Jefferson “It is very true, that the way you think creates reality for yourself.” – Oprah Winfrey “In the last analysis, what we are communicates far more eloquently than anything we say or do.” ~ Stephen…

  • Pharmaceutical Reps Have To Work Smarter Now

    Clint Cora
    21 Oct 2011 | 6:30 am
    photo credit: Sam 17 Pharmaceutical Reps Affected By Regulations In the US, there have been certain regulations that came into effect that changed the way pharmaceutical reps work.  If you go to doctors’ offices and see all sorts of trinkets, pens, notepads and other types of stuff that have a name of some drug on it as promotion, these were all supplied to by pharmaceutical reps.  Indeed, one of the main tasks of the pharmaceutical representative was to distribute such promotional items to as many doctors and their staff as possible. It seemed like an easy part of the pharmaceutical…
  • add this feed to my.Alltop

    Latest Featured Articles

  • Pharma forecasting: The changing role of patients

    Andrew Tolve
    17 Jan 2012 | 6:32 am
    Précis:  Milos Graonic, senior vice president, global leader of Nielsen BASES Pharmaceutical Practice, on how to mine patient data for forecasting insights The intersection of the Internet, social media, and mobile has created a new dynamic in healthcare. Today’s patients have more access to information and to each other and can thus exert more influence on their treatments and the healthcare system at large. Related Content:  Special report: Patient's Week 2011 Forecasting 2.0: How to make forecasting a strategic imperative Image:  Primary Event:  Forecasting…

  • Q&A: Making adherence effective, economic and scalable

    Editor
    11 Jan 2012 | 8:38 am
    Précis:  Professors John Weinman of Kings College London and Keith Petrie of the University of Auckland on the future of medication adherence Professors John Weinman, Kings College London, and Keith Petrie, the University of Auckland, are two of the most prominent researchers in medication adherence. Their research has greatly increased our understanding of the factors affecting patient behavior and the ways in which adherence to prescribed medication can be improved. In this interview with Atlantis Healthcare, they discuss how our understanding of treatment adherence has developed,…

  • Emerging pharma markets: How to profit in Latin America

    Ursula Sautter
    6 Jan 2012 | 7:44 am
    Précis:  Eyeforpharma's Ursula Sautter talks to Rafael Quintanilla Chong, head of primary care at Bayer Healthcare Mexico, about the promise of the Latin American market Pharma companies are increasingly looking to Latin America as an attractive new market. The region's economies are "being sustained largely by private consumption, thanks to an improvement in labor indicators and an expansion in lending," the UN’s Economic Commission for Latin America and the Caribbean (ECLAC) stated last summer. "Expectations of buoyant domestic demand and the depletion of…

  • Understanding pharma’s drug development costs

    Angelo DePalma
    3 Jan 2012 | 10:13 am
    Précis:  Angelo DePalma explores what it costs to bring a new drug to market—and why it matters Real or imagined, high research costs have been spun into a virtue, a bottomless font of goodwill that borders at times on sympathy. Since the Kefauver hearings in the US 50 years ago, the pharma industry has pointed to research costs to justify pricing. Calculating actual costs is where everyone seems to run into trouble. Related Content:  Patent expiration: Innovate or die New models for drug discovery and marketing Image:  Primary Event:  Clinical Commercial Europe 2012…

  • Dr. Bates’ Talkback: How to profitably compete in the oncology market

    Andree Bates
    13 Dec 2011 | 9:54 am
    Précis:  Dr. Andree K. Bates outlines key strategies for addressing the sales, marketing and market access challenges of the oncology market On the face of it, marketing oncology drugs is a highly lucrative business for the pharmaceutical industry. Patients with cancer are increasing at higher levels than many conditions. In fact, cancer is the leading cause of death in people under 85. Related Content:  New models for market access Market access: How network intelligence increases value Image:  Primary Event:  Oncology Market Access USA Premium`:  No read more
 
  • add this feed to my.Alltop

    Vaccine News

  • Gen X largely shrugged off call for H1N1 shots

    John Carroll
    26 Jan 2012 | 9:36 am
    About 2 of every 3 American adults aged 36 to 39 tracked the frenzy of reports that erupted after the swine flu pandemic broke out and concluded that there was something there that was at least mildly concerning. But in the end only 1 of every 5 went to the trouble of being vaccinated against it, according to a new study. And Generation X turned to friends, co-workers and families for the information they trusted the most. "In the decades ahead, the young adults in Generation X will encounter numerous other crises--some biomedical, some environmental and others yet to be…

  • Hep A vax study underscores need for long-term campaigns

    John Carroll
    26 Jan 2012 | 9:30 am
    A new survey out from the CDC demonstrates just how potent a recommendation for vaccinations can be, and how quickly parents can overlook a jab when they aren't being urged repeatedly to provide one. Overall, new research indicates that only 3 out of every 10 children in the U.S. have received both recommended hepatitis A vaccinations. In the 11 states where recommendations have been in place for the longest period of time, the Centers for Disease Control and Prevention found that 60% of all kids had both shots before reaching 17. Two states, Alaska and Oklahoma, achieved 85% compliance. In…

  • Late-stage Galena vax offers hope for breast cancer patients

    Liz Jones Hollis
    25 Jan 2012 | 3:54 pm
    Oregon's Galena Biopharma ($GALE) is edging closer to a submission for NeuVax after the initiation of a Phase III trial for its vaccine to prevent HER2 1+ and 2+ breast cancer recurrence in the adjuvant setting. The trial--the timing of which beats some analyst predictions--could help stealthy Galena land an approval for a potential blockbuster, Zacks notes. Each year, more than 200,000 women in the U.S. are diagnosed with breast cancer, and 75% test positive for HER2. However, only 25% are eligible for Roche-Genentech's Herceptin. Looking to aid those patients who…

  • Common chemicals threaten childhood vaccines

    Mark Hollmer
    25 Jan 2012 | 2:03 pm
    Be careful about those microwave popcorn bags. They may threaten the viability of children's vaccinations. More precisely, the Harvard School of Public Health's Philippe Grandjean thinks children exposed to perfluorinated compounds may not respond as well to vaccines versus kids without the exposure. Even worse, that exposure may work its damage before the child is even born, Grandjean's research concludes. As a USA Today story on the finding somberly points out, the chemical is in many, many things, from some non-stick cookware to paper plates to stain-resistant coatings on…

  • Researchers target multiple tumors in new cancer vaccine study

    Ryan McBride
    25 Jan 2012 | 11:01 am
    Targeting a variety of tumor types, the Roswell Park Cancer Institute has begun recruiting patients for an early-stage clinical trial to test an experimental cancer vaccine. The vaccine, or immunotherapy, is designed to lure the immune system's attacker T cells to tumor sites, and the researchers have a new trick up their sleeves to sustain the attack on cancers longer than similar past attempts. Roswell Park aims to bring 18 to 20 patients into the Phase I study, and, as is typical of many early-stage cancer drug trials, the researchers are open to recruiting subjects with a variety of…
  • add this feed to my.Alltop

    FiercePharmaManufacturing

  • Lonza board boots CEO Borgas

    George Miller
    26 Jan 2012 | 9:49 am
    Pressure from Asian low-cost chemical and drug ingredient suppliers, combined with high Swiss energy costs impacting manufacturing operations, have yielded poor financial performance at Lonza and the ouster of CEO Stefan Borgas. "Our decision to replace Borgas was made during the past 48 hours and is backed by the board and management," said board chairman and acting-CEO Rolf Soiron. Story

  • Ranbaxy, FDA enter consent decree over GMP, data breaches

    George Miller
    26 Jan 2012 | 8:36 am
    Plans for the $500 million that Daiichi Sankyo set aside to get problem child Ranbaxy out of regulatory jail became clearer Wednesday with the filing of a consent decree. The Indian-based drugmaker and the FDA have agreed to terms that will allow the manufacturer to end several years of market restrictions imposed by the regulator for manufacturing and data-reporting violations. The court action stems from issues stretching back to 2008. Prominent among them was the company's inadequate separation of penicillin and non-penicillin drug production and inadequate attempts to prevent the…

  • Warnings analysis spotlights analytics weakness

    George Miller
    26 Jan 2012 | 7:11 am
    Analytics issues appear in the majority of FDA warning letter citations for manufacturing, including unvalidated methods and inadequate procedures for responding to out-of-spec test results. The European Compliance Academy reported the findings after reviewing warning letters issued to 14 makers of drug ingredients. The academy noted 2011 saw a nearly three times rise in the number of warning letters issued to such manufacturers. Companies in the U.S. and China led in terms of warnings with four each. India garnered three while China, Spain and the U.K. each earned one apiece.

  • Owner arrested in Pakistani drug deaths cites Big Pharma conspiracy

    George Miller
    26 Jan 2012 | 6:18 am
    A Big Pharma conspiracy and hospital error are possibly behind the deaths of dozens of heart patients, said the owner of a Pakistani drug manufacturer arrested in the case. His conspiracy theory chalks up the incident to "propaganda" from multinational companies to "suppress the local industry," reports The Express Tribune. The unnamed owner was one of three arrested on charges of manufacturing "substandard" heart medication administered by the Punjab Institute of Cardiology, according to the report. The three manufacturers are Alfalah Pharma, Mega Pharmaceuticals and…

  • Merck 'program of projects' earns facility award

    George Miller
    25 Jan 2012 | 3:43 pm
    Merck's ($MRK) vaccine unit has been named winner of the Facility of the Year Award in the facility integration category. Rentschler Biotechnologie was named winner for equipment innovation at its Laupheim, Germany, manufacturing plant. According to award program details, Merck was facing a shortfall at its Varicella vaccine franchise. It launched a "program of projects" at its vaccine bulk manufacturing facility in Durham, NC. The team used a modular construction strategy for off-site fabrication and equipment testing to speed the work. The resulting 214,000-square-foot facility doubled the…
  • add this feed to my.Alltop

    fiercemedicaldevices.com

  • Roche's $5.7B Illumina bid risks standing alone

    Mark Hollmer
    27 Jan 2012 | 12:47 pm
    In the wake of Roche's ($RHHBY) $5.7 billion hostile takeover bid for gene sequencing company Illumina ($ILMN), the jury is still out as to what it means for the industry at large. On the one hand, as Bloomberg is reporting, the push to bring DNA scanning into more routine medical use may lead to similar deals. Illumina competes with Life Technologies ($LIFE), Affymetrix ($AFFX), and others that might also make good takeover targets. Though their customers are primarily scientists rather than hospitals, the article correctly notes that the $1.5 billion market for gene sequencing machines…

  • Abbott to cut 700 jobs as Promus sales decline

    Liz Jones Hollis
    26 Jan 2012 | 8:22 am
    Despite reporting healthy profits this week, Abbott Labs ($ABT) is laying off 700 people in the U.S. and Puerto Rico as part of a restructuring effort. Roughly 200 positions will be eliminated at its Lake County, IL, campus, as the company discontinues some of its mature products in the hospital and laboratory diagnostics division, the Chicago Tribune notes. The company, which saw net earnings of about $1.62 billion in Q4, also is making cuts in its stent-manufacturing business, a move that will affect workers in California, company…

  • CN Creative nails $3.1M for electronic inhaler smoking cessation device

    Mark Hollmer
    25 Jan 2012 | 10:11 am
    CN Creative has secured $3.1 million in new financing to fund final development work for its electronic inhaler nicotine replacement therapy device to help patients quit smoking. Advent Life Sciences led the Series A financing round for the U.K. company, which will take the Nicadex device through final clinical reviews and then regulatory submissions to the U.K.'s Medicines and Healthcare products Regulatory Agency and, finally, the FDA in the U.S. Plans call for marketing the Nicadex inhaler as a medically supervised device designed to help patients quit smoking as part of a larger smoking…

  • Mevion scores $45M for proton therapy system

    Liz Jones Hollis
    25 Jan 2012 | 9:42 am
    Mevion Medical Systems has closed a $45 million investment from ProQuest Investments and existing investors, including Caxton Health Life Sciences, Venrock and CHL Medical Partners. The privately held, Littleton, MA-based company is focused on manufacturing its Mevion S250 proton therapy system and hopes its technology can provide a workaround for the hefty price tag ($120 million+) of most U.S. proton therapy centers, according to DOTmed. Mevion hopes its efforts will make cancer therapy more readily available to those patients who may benefit from this advanced form of…

  • St. Jude continues to see CRM sales slip as quarterly profit falls

    Liz Jones Hollis
    25 Jan 2012 | 7:43 am
    Facing pressures in its cardiac rhythm management unit, St. Jude Medical ($STJ) saw its net earnings for fourth-quarter 2011 come in at $163 million, down from $206 million the previous year. The company was in part hurt by CRM sales, which dipped 4% to $728 million as the market for such products as pacemakers and ICDs remained tough. In fact, the CRM market shrank roughly 4% during 2011, St. Jude CEO Daniel Starks said during the call. The company experienced some bumps in the last quarter, particularly after the FDA classified its Nov. 28 voluntary medical device…
 
  • add this feed to my.Alltop

    Pharmalot

  • Third Time Lucky: FDA Approves Bydureon

    Ed Silverman
    27 Jan 2012 | 2:49 pm
    Nearly two years after the FDA issued what was the first of two rejections, the agency has finally approved the Bydureon diabetes treatment, setting up what is going to be heated battle between Amylin Pharmaceuticals, which will market the drug, and Novo Nordisk, which sells a rival medicine called Victoza. Both drugs are part of the GLP-1 class of diabetes medications (read the FDA letter). The approval was largely expected, given that Amylin had labored to appease the agency, which asked the drugmaker last fall - when the second of two complete response letters was issued - to conduct an…

  • Boehringer, A Journal Article & Discredited Pharma

    Ed Silverman
    27 Jan 2012 | 10:21 am
    Last year, a publication in the UK called Future Prescriber ran an article written by two physicians that touted the virtues of Trajenta, a treatment for Type 2 diabetes that Boehringer Ingelheim and Eli Lilly were about to jointly market in Europe. However, there were some problems with the article, which prompted a general practitioner to complain about a host of exaggerations and misleading statements. How did this happen? The article is the latest example of a drugmaker and a publication working together to promote a medication in a way that can cause the average practitioner to get the…

  • Pfizer Sued By Employees Over Retirement Plans

    Ed Silverman
    27 Jan 2012 | 8:46 am
    Between 2000 and 2009, Pfizer stock did not fare so well. As this chart indicates, the shares began the decade hovering around $45, but then dipped to below $14. And so a group of Pfizer employees have filed a lawsuit against the drugmaker, claiming their retirements plans took a beating because these held a disproportionate amount of Pfizer stock. During that stretch, you may recall, Pfizer paid big bucks to swallow up some of its biggest rivals - Warner-Lambert and Pharmacia - in order to gain some key medicines. But the Pharmacia deal, in particular, was followed by controversy over the…

  • Surprise! James Murdoch Leaves The Glaxo Board

    Ed Silverman
    27 Jan 2012 | 7:56 am
    Months after we asked whether James Murdoch should remain on the GlaxoSmithKline board (back story), the embattled scion of the Murdoch media empire has decided not to stand for re-election at the upcoming annual shareholder meeting to be held this May. At least, that is the wording in an official statement released this morning by the drugmaker. His three-year stint as a non-executive director has been under a cloud ever since a scandal erupted over charges that various employees in the Murdoch media empire in the UK hacked into phones belonging to families of murder victims, terror victims,…

  • Up And Down The Ladder… Job Changes

    Ed Silverman
    27 Jan 2012 | 7:50 am
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Savient Pharmaceuticals promoted Stephen…
Log in